CD274 and non-small cell lung carcinoma: In NSCLC patients treated with PD-1/PD-L1 inhibitors, an increase in relative eosinophil count (REC) at 4 weeks (from ∼1.8% to 4.4%) was independently associated with superior disease control and OS (p < 0.001) [31].